Announcement PDF ASX : EMD Delivering the new paradigm in mental health care April 2026 Ignite Investment Summit Singapore Advanced therapies. Compassionate care. 2 Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions. This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Advanced therapies. Compassionate care. 3 Corporate Overview ASX: EMD Trading Information Last Traded Share Price A$0.056 12-Month low / high A$0.023 / 0.078 Shares Outstanding 806,483,233 Unlisted Options (including loyalty options) 310,147,902 Market Capitalisation 1 ~A$45m Last Reported Cash Position 2 ~A$10.5m NOTES: 1. As of market close 20 April 2026 2. As reported in December 2025 Quarterly Report Substantial Shareholder Shareholder % #1 Holder: Greg Hutchinson, Exec. Chairman 5.29% Shareholding Top 50 Share Price Advanced therapies. Compassionate care. 4 Globally Mental Health Illness Is a Rising Chronic Health Problem The global prevalence of mental health disorders is escalating at a staggering pace; it has now reached 13.6%2 Over a billion people living with mental health conditions - services require urgent scale up1 “Transforming mental health services is one of the most pressing public health challenges,” WHO Director-General Dr Tedros Adhanom Ghebreyesus SOURCES: 1. https://www.who.int/news/item/02-09-2025-over-a-billion-people-living-with-mental-health-conditions-services-require-urgent-scale-up 2. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00261-0/fulltext 3. Australian Financial Review, May 17 2025 “Mental health is the new pandemic but the provision of mental health … services is very fragmented, not only in Australia but everywhere3 ” Bupa Group CEO - Inaki Ereno May 17, 2025 - 9.00am May 17, 2025 - 9.00am Advanced therapies. Compassionate care. 5 Significant Global Research in Psychedelic Drugs More than 50 psychedelic-assisted therapy programs currently in development globally1 US President Donald Trump signs Executive Order to fast-track research and patient access to psychedelic drugs2 EMD uniquely positioned to support these companies through existing clinical network from clinical trial execution and post-approval commercial roll-out3 1. Psychedelic Alpha, Psychedelic Drug Development Tracker: https://psychedelicalpha.com/resources/psychedelic-drug-development-tracker/ 2. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/ 3. Refer ASX announcement 20 April 2026 Psyence Biomed Advanced therapies. Compassionate care. 6 Australia is the FIRST jurisdiction in the world to reschedule two promising treatments MDMA-assisted therapy for PTSD Psilocybin-assisted therapy for Depression Australia’s Unique Opportunity An Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions 1. Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists | Therapeutic Goods Administration (TGA) Advanced therapies. Compassionate care. 7 Advanced therapies. Compassionate care. Who is Emyria VISION To develop and implement a sophisticated, safe model for psychedelic-assisted mental health care - so emerging therapies can be delivered responsibly at scale. MISSION Emyria is establishing a network of clinics to expand at pace in a capital light fashion SOURCES: 1. See ASX release 14 April 2025 2. See ASX release 29 July 2025 3. See ASX release 10 November 2025 4. See ASX release 16 December 2025 Current Sites 1 2 3 Near term potential sites 4 Advanced therapies. Compassionate care. 8 SCREENING AND PREPARATION ACTIVE TREATMENT PROTOCOL FOLLOW-UP PERIOD (12 months from last Treatment Cycle) Dosing Day 1 (8 hrs) Follow up Therapy Sessions x 3 Each dosing cycle (medication and therapy) ~$10,000 / patient Emyria’s P-AT Treatment Model Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up Dosing Day 2 (8 hrs) Follow up Therapy Sessions x 3 Dosing Day 3 (8 hrs) PTSD only Follow up Therapy Sessions x 3 DOSING CYCLE 1 DOSING CYCLE 2 DOSING CYCLE 3 Advanced therapies. Compassionate care. 9 PCL-5 SCORE 1 SOURCES: 1. The PCL-5 is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to diagnostic DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition). Date 2018 2019 2020 2021 2022 2023 2024 5 years MDMA-AT commenced 24m 0 10 20 30 40 50 60 70 PCL-5 < 30 Kate’s story: First responder • PTSD due to cumulative workplace traumas • Myriad of therapies: EMDR, in-vivo, ACT, CBT, mindfulness, somatic exercises, TMS, imagery rescripting, nightmare rescripting. Different psychotropic medications • Stuck, terrified and tortured by her unrelenting symptoms and her psychological defenses. • Despite all efforts and commitment, treatment and therapy resistant 6m following MDMA-AT, Kate returned to work after nearly 5 years away. More than 12m after treatment, Kate remains in remission. (i.e. PCL-5 < 32) Emyria’s PTSD Program Is Delivering Results Case Study Kate | From “Permanent Disability” To Back at Work 2025 2026 Remission Line Advanced therapies. Compassionate care. 10 Emyria’s PTSD Program Is Delivering Durable Results Durable symptom and quality of life improvement, beyond 12 months SOURCES: 1. The PCL-5 is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to diagnostic DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition). Baseline Cycle 1 Cycle 2 Cycle 3 6 months after end of treatment 12 months after end of treatment Average PCL-5 1 Scores by Visit (up to 12 months follow-up) Typical last treatment Patients continue to improve after active treatment has ended. ~67% of patients no longer meet criteria for PTSD diagnosis Emyria Real-World Data as of Dec 31st 2025 ~76% of patients have a clinically significant improvement Advanced therapies. Compassionate care. 11 Third Party Fundin g Dedicated Facilities Proven Clinical Model Regulatory approvals 100+ Trained Skilled Clinicians Secure Drug Supply Emyria Has Developed Significant Scalable Delivery IP and Know How Advanced therapies. Compassionate care. 11 Advanced therapies. Compassionate care. 12 Total Addressable Australian Market | PTSD +TRD Adults with difficult to treat PTSD and TRD in Australia SOURCES: 1. https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release#key-statistics 2. Average full treatment cost assuming 3 treatment cycles completed 3. Average full treatment cost assuming 2 treatment cycles completed Australian Adults With PTSD ~1,500,0001 ~7% of all adults ~$33,000 / Treatment 2 Australian Adults With Major Depression ~1,100,0001 ~4% of adults have Major Depressive Disorder ~$22,000 / Treatment 3 Advanced therapies. Compassionate care. 13 Emyria | Why Invest First mover advantage globally Significant Total Addressable Market globally Operationalised the delivery of PAT at Scale Generating revenue Capital Light approach to clinics expansion Delivering durable outcomes Advanced therapies. Compassionate care. 14 Emyria Board Significant Clinical Services & Global Innovation Expertise Greg Hutchinson Executive Chairman Health Service Leadership: 5D Clinics Former CEO Sonic HealthPlus leading 40+ clinics Dr Michael Winlo Executive Director Research & Data Expertise: Ex-Palantir healthcare lead, Medical Doctor and Stanford MBA Dr Karen Smith Non-Executive Director Biopharma Executive: 100+ clinical trials and 20+ regulatory approvals; Former Chief Medical Officer and Global Head of R&D at Jazz Pharma Dr Mohit Kaushal Non-Executive Director Health IT Strategist: Key role in Oak Street Health's $10.6B acquisition by CVS Health; Served in Obama’s Health IT task force; Adjunct Professor at Stanford Prof Sir John Tooke Non-Executive Director Clinical Service & Health Payer Expertise: Former President of the Academy of Medical Sciences, influential roles at BUPA and past advisor to Google DeepMind Contact Information Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Investor / Media Inquiries investors@emyria.com Visit Our Investor Hub